By Fineline Cube 
Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest over USD 700 million in constructing a state-of-the-art drug manufacturing facility in Holly Springs, North Carolina, spanning 700,000 square feet.
Employment Impact
The project is expected to create over 400 high-wage manufacturing jobs once operational and more than 1,500 temporary construction jobs during the development phase.
Facility Purpose and Future Potential
The facility will enhance production capabilities for Roche and Genentech’s pipeline of next-generation obesity therapies. Future expansions will be considered based on business demands and the U.S. regulatory landscape.
Current US Presence
Roche and Genentech currently maintain a significant U.S. presence, operating 13 manufacturing sites and 15 R&D facilities across eight states, with 25,000 employees in 24 locations.-Fineline Info & Tech